| Not Yet Recruiting | eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation NCT07469592 | University of Miami | N/A |
| Not Yet Recruiting | CD34+ Transplants for Leukemia and Lymphoma NCT05565105 | Guenther Koehne | Phase 2 |
| Not Yet Recruiting | Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) NCT06345027 | Baylor College of Medicine | Phase 1 |
| Not Yet Recruiting | Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW NCT07269067 | University Hospital, Bordeaux | — |
| Withdrawn | Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for In NCT06770257 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Le NCT07216443 | Orca Biosystems, Inc. | Phase 2 |
| Recruiting | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Mye NCT06852222 | Janssen Research & Development, LLC | Phase 3 |
| Recruiting | Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML NCT06580106 | Wake Forest University Health Sciences | — |
| Recruiting | A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms NCT06651229 | Janssen Research & Development, LLC | Phase 1 |
| Enrolling By Invitation | Daunorubicin + Cytarabine + Venetoclax in de Novo AML NCT06697327 | Anhui Medical University | N/A |
| Recruiting | A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms NCT06618001 | Janssen Research & Development, LLC | Phase 1 |
| Enrolling By Invitation | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring NCT06788509 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Bla NCT06643962 | Affiliated Hospital of Nantong University | N/A |
| Not Yet Recruiting | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Foll NCT05628623 | Eastern Cooperative Oncology Group | Phase 2 |
| Not Yet Recruiting | Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia NCT06559644 | The First Affiliated Hospital of Soochow University | EARLY_Phase 1 |
| Recruiting | MB-dNPM1-TCR.1 in Relapsed/Refractory AML NCT06424340 | Miltenyi Biomedicine GmbH | Phase 1 / Phase 2 |
| Recruiting | A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed NCT06384261 | OncoVerity, Inc. | Phase 2 |
| Recruiting | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrom NCT06501196 | BlossomHill Therapeutics | Phase 1 |
| Recruiting | DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia NCT06382168 | Delta-Fly Pharma, Inc. | Phase 1 / Phase 2 |
| Recruiting | Interest of Light Therapy in Hematology - The PHOTO-TREAT Study NCT06326268 | Institut de cancérologie Strasbourg Europe | N/A |
| Recruiting | Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT06118788 | Guangzhou Bio-gene Technology Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML NCT05945849 | University of Pennsylvania | Phase 1 |
| Recruiting | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06001788 | Kura Oncology, Inc. | Phase 1 |
| Active Not Recruiting | A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic NCT05883956 | Otsuka Australia Pharmaceutical Pty Ltd | Phase 3 |
| Terminated | Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogene NCT05984199 | Vor Biopharma | Phase 1 / Phase 2 |
| Active Not Recruiting | Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Tr NCT05968963 | University of Miami | N/A |
| Active Not Recruiting | Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment NCT05774990 | University of Southern Denmark | — |
| Recruiting | Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT NCT05682755 | Sichuan University | Phase 1 / Phase 2 |
| Recruiting | VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid NCT05603884 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Unknown | Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies NCT05583175 | Xianmin Song, MD | Phase 2 |
| Completed | High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology NCT04940468 | University of Colorado, Denver | N/A |
| Completed | Post-transplant Flotetuzumab for AML NCT05506956 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Active Not Recruiting | A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies NCT05453903 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid L NCT05319587 | Moleculin Biotech, Inc. | Phase 1 / Phase 2 |
| Terminated | A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Phar NCT05424380 | GlaxoSmithKline | Phase 1 |
| Completed | Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Pat NCT05471700 | Zhujiang Hospital | N/A |
| Active Not Recruiting | An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With NCT05413018 | Bristol-Myers Squibb | Phase 2 |
| Active Not Recruiting | Vyxeos for Induction of Low- or Intermediate-risk. NCT05599360 | Shaare Zedek Medical Center | Phase 2 |
| Completed | CD155 Expression in Acute Myeloid Leukemia NCT06369662 | Assiut University | — |
| Unknown | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantat NCT05005299 | Melbourne Health | Phase 1 |
| Unknown | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic NCT05154474 | Weprom | — |
| Terminated | A Long-term Follow-up Study of Patients Who Received VOR33 NCT05309733 | Vor Biopharma | — |
| Recruiting | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) NCT04988555 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and NCT05218902 | Bristol-Myers Squibb | — |
| Recruiting | Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Rel NCT05270200 | Zhujiang Hospital | Phase 1 / Phase 2 |
| Terminated | A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndr NCT05168202 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML NCT05305859 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Unknown | Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia NCT05008575 | Xinqiao Hospital of Chongqing | Phase 1 |
| Terminated | Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatmen NCT04849910 | Vor Biopharma | Phase 1 / Phase 2 |
| Terminated | Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory NCT04951778 | Celgene | Phase 1 |
| Completed | A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Part NCT04887857 | Celgene | Phase 1 |
| Unknown | Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia NCT05016063 | Xinqiao Hospital of Chongqing | EARLY_Phase 1 |
| Terminated | Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML) NCT04920188 | UNC Lineberger Comprehensive Cancer Center | — |
| Unknown | A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for New NCT04824924 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Unknown | Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine NCT04687761 | PETHEMA Foundation | Phase 1 / Phase 2 |
| Withdrawn | Acute Myeloid Leukemia Real World Treatment Patterns NCT04230564 | Pfizer | — |
| Recruiting | Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors NCT06785077 | European Institute of Oncology | N/A |
| Unknown | ObServatory Children Acute RElated Therapy Leukemia NCT04450784 | University Hospital, Bordeaux | — |
| Completed | IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT NCT04522895 | Heinrich-Heine University, Duesseldorf | Phase 2 |
| Terminated | A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia NCT04336982 | Celgene | Phase 1 |
| Terminated | A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Le NCT04209725 | SCRI Development Innovations, LLC | Phase 2 |
| Withdrawn | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosp NCT04361058 | SCRI Development Innovations, LLC | Phase 1 |
| Completed | A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Rece NCT04337138 | Pfizer | — |
| Completed | A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia o NCT04241549 | OncoVerity, Inc. | Phase 1 |
| Terminated | Natural Killer Cell (CYNK-001) Infusions in Adults with AML NCT04310592 | Celularity Incorporated | Phase 1 |
| Active Not Recruiting | Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukem NCT04150887 | OncoVerity, Inc. | Phase 1 |
| Completed | Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) i NCT03690115 | Versailles Hospital | Phase 2 |
| Unknown | Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia NCT04272125 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Completed | An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies NCT04052126 | Centre Leon Berard | N/A |
| Terminated | Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage NCT03926624 | Delta-Fly Pharma, Inc. | Phase 3 |
| Withdrawn | HDM201 Added to CT in R/R or Newly Diagnosed AML NCT03760445 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid Leu NCT04133220 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not NCT04090736 | PETHEMA Foundation | Phase 3 |
| Terminated | Oral Health Condition and Quality of Life in Children With Leukemia NCT04968860 | Paulo Sergio da Silva Santos | — |
| Unknown | CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia NCT04265963 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Terminated | Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia NCT03988205 | Medical College of Wisconsin | Phase 4 |
| Active Not Recruiting | A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are No NCT04023526 | OncoVerity, Inc. | Phase 2 |
| Completed | A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems NCT03814005 | Takeda | Phase 1 |
| Terminated | Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Su NCT03549351 | University Hospital Heidelberg | — |
| Completed | A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodyspl NCT03915379 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43 NCT03850574 | Aptose Biosciences Inc. | Phase 1 / Phase 2 |
| Completed | Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Pati NCT03823352 | Golden Biotechnology Corporation | Phase 2 |
| Completed | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) NCT03388749 | Moleculin Biotech, Inc. | Phase 1 / Phase 2 |
| Unknown | Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consoli NCT03796533 | Hospices Civils de Lyon | N/A |
| Completed | Cardiovascular Function in Acute Leukemia NCT03760237 | Abramson Cancer Center at Penn Medicine | — |
| Unknown | Efficacy of FLAG Regimen for the Treatment of Patients With AML NCT03600558 | Tianjin Medical University General Hospital | — |
| Terminated | Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias NCT03761069 | PTC Therapeutics | Phase 1 |
| Completed | A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients NCT03720366 | Celgene | Phase 1 |
| Recruiting | Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT NCT03793517 | Peking University People's Hospital | Phase 2 / Phase 3 |
| Unknown | Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelod NCT03235973 | Institut Paoli-Calmettes | Phase 1 |
| Completed | A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib I NCT03416179 | Pfizer | Phase 3 |
| Completed | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) NCT03315039 | Moleculin Biotech, Inc. | Phase 1 / Phase 2 |
| Unknown | CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML） NCT03556982 | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Phase 1 / Phase 2 |
| Completed | Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain NCT03435341 | Celgene | — |
| Terminated | NLA101 in Adults Receiving High Dose Chemotherapy for AML NCT03301597 | Nohla Therapeutics, Inc. | Phase 2 |
| Completed | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Hi NCT03268954 | Takeda | Phase 3 |
| Completed | A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in NCT03298516 | Genentech, Inc. | Phase 1 |
| Unknown | Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in NCT03287128 | Versailles Hospital | — |
| Completed | Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia NCT03335267 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS NCT03066648 | Novartis Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untre NCT03173248 | Institut de Recherches Internationales Servier | Phase 3 |
| Completed | BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) NCT03127735 | Bayer | Phase 1 |
| Unknown | B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) NCT02493829 | King's College London | Phase 1 |
| Terminated | DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) NCT03110354 | Daiichi Sankyo | Phase 1 |
| Unknown | Precision Exercise in Children With Malignant Hemopathies NCT04090268 | University of Milano Bicocca | N/A |
| Unknown | Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy NCT02856464 | King's College Hospital NHS Trust | Phase 2 |
| Completed | Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplicatio NCT02984995 | Daiichi Sankyo Co., Ltd. | Phase 2 |
| Completed | King's Invasive Aspergillosis Study II NCT02875743 | King's College Hospital NHS Trust | Phase 4 |
| Completed | A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemi NCT03030612 | OncoVerity, Inc. | Phase 1 / Phase 2 |
| Terminated | A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or NCT02848001 | Celgene | Phase 1 |
| Withdrawn | A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia NCT02527174 | University of Alberta | Phase 1 |
| Withdrawn | A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age NCT02722135 | Boehringer Ingelheim | Phase 1 |
| Terminated | A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes NCT02841540 | Hemavant Sciences GmbH | Phase 1 |
| Completed | A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance NCT02842229 | Celgene | — |
| Terminated | A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcu NCT02781467 | Celularity Incorporated | Phase 1 |
| Completed | A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acut NCT02632721 | Boehringer Ingelheim | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targete NCT02677922 | Celgene | Phase 1 / Phase 2 |
| Completed | An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previous NCT02775903 | Celgene | Phase 2 |
| Completed | PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients NCT02928523 | MaaT Pharma | Phase 1 / Phase 2 |
| Completed | Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refrac NCT02715011 | Janssen Research & Development, LLC | Phase 1 |
| Active Not Recruiting | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leu NCT02665065 | Actinium Pharmaceuticals | Phase 3 |
| Completed | A Study of Pevonedistat in Adult East Asian Participants NCT02782468 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants NCT02610777 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Unknown | Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia NCT02682732 | Hamilton Health Sciences Corporation | N/A |
| Completed | Prophylactic Application of Donor-derived TCM After Allogeneic HSCT NCT02758223 | Wuerzburg University Hospital | Phase 1 / Phase 2 |
| Unknown | Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias NCT02759822 | Leonardo Javier Arcuri | — |
| Completed | A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patien NCT02670044 | Hoffmann-La Roche | Phase 1 |
| Terminated | A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) NCT02641002 | Celgene | Phase 1 |
| Terminated | A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refract NCT02545283 | Hoffmann-La Roche | Phase 3 |
| Terminated | Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreat NCT02485353 | Hamid Sayar | N/A |
| Completed | A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloi NCT02450877 | Celgene | Phase 2 |
| Completed | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Deci NCT02472145 | Janssen Research & Development, LLC | Phase 2 / Phase 3 |
| Unknown | ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia NCT02619071 | Institut Paoli-Calmettes | N/A |
| Completed | Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT NCT02472691 | Heinrich-Heine University, Duesseldorf | Phase 2 |
| Completed | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remissi NCT02348489 | Astex Pharmaceuticals, Inc. | Phase 3 |
| Completed | Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML NCT02306291 | GlycoMimetics Incorporated | Phase 1 / Phase 2 |
| Unknown | Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML NCT02427919 | Seoul St. Mary's Hospital | Phase 2 / Phase 3 |
| Unknown | A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation ( NCT02328950 | Fujian Medical University | — |
| Unknown | Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia NCT02345915 | Institut Paoli-Calmettes | N/A |
| Completed | Phase I, Dose Escalation Study of Decitabine NCT02264873 | University of Florida | Phase 1 |
| Terminated | Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrom NCT01898793 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantati NCT02337595 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 1 / Phase 2 |
| Completed | Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Ce NCT02117115 | Washington University School of Medicine | EARLY_Phase 1 |
| Unknown | Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patie NCT02140606 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients NCT02057770 | Washington University School of Medicine | Phase 1 |
| Terminated | Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) NCT02003573 | Boehringer Ingelheim | Phase 1 |
| Terminated | Connect® Myeloid Disease Registry NCT01688011 | Celgene | — |
| Completed | Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Tran NCT01835587 | Celgene | Phase 1 / Phase 2 |
| Completed | Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid L NCT01757535 | Celgene | Phase 3 |
| Terminated | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation NCT01747499 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes NCT01687400 | Washington University School of Medicine | Phase 2 |
| Completed | Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreat NCT01721876 | Boehringer Ingelheim | Phase 3 |
| Completed | CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic NCT03393611 | Weill Medical College of Cornell University | Phase 1 |
| Completed | BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With NCT01690624 | Boehringer Ingelheim | Phase 1 |
| Completed | Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS NCT01617226 | University of Birmingham | Phase 2 |
| Completed | Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) NCT01662505 | Boehringer Ingelheim | Phase 1 |
| Completed | A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission NCT01632852 | CSL Limited | Phase 1 |
| Completed | An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in NCT02891551 | Celgene | — |
| Completed | Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematologic NCT02164071 | Celgene | — |
| Completed | Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia NCT01390311 | Washington University School of Medicine | Phase 1 |
| Completed | Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refrac NCT01565668 | Daiichi Sankyo | Phase 2 |
| Completed | A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) NCT01468467 | Daiichi Sankyo | Phase 1 |
| Completed | Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine NCT01519011 | Celgene | Phase 1 |
| Completed | Risk-adapted Therapy for Primary Acute Myeloid Leukemia NCT04687098 | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | Phase 2 |
| Completed | A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute NCT01390337 | Daiichi Sankyo | Phase 1 |
| Completed | Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia NCT01518556 | Konkuk University Medical Center | Phase 1 / Phase 2 |
| Completed | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors NCT01158118 | Washington University School of Medicine | Phase 2 |
| Completed | A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in NCT02921815 | Celgene | — |
| Completed | Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia NCT01976442 | University of Rochester | — |
| Terminated | Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patien NCT01246752 | University Hospital Carl Gustav Carus | Phase 3 |
| Completed | Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia NCT00906945 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasiv NCT01249820 | Radboud University Medical Center | Phase 2 |
| Completed | Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML NCT01161550 | Washington University School of Medicine | Phase 1 |
| Terminated | MSC and HSC Coinfusion in Mismatched Minitransplants NCT01045382 | University of Liege | Phase 2 |
| Terminated | IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) NCT01027923 | Washington University School of Medicine | Phase 1 |
| Completed | Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) NCT01001143 | Washington University School of Medicine | Phase 1 |
| Completed | Azacitidine and Lenalidomide for Acute Myeloid Leukemia NCT01016600 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant NCT00986804 | Washington University School of Medicine | Phase 1 |
| Unknown | Unrelated Double Umbilical Cord Blood Units Transplantation NCT01015742 | Tehran University of Medical Sciences | Phase 2 / Phase 3 |
| Terminated | Trial of Pimasertib in Hematological Malignancies NCT00957580 | EMD Serono | Phase 2 |
| Terminated | Pilot Study of Unrelated Cord Blood Transplantation NCT00916045 | King's College Hospital NHS Trust | Phase 2 |
| Completed | Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodyspl NCT00875745 | Indiana University School of Medicine | Phase 1 |
| Completed | Sitagliptin Umbilical Cord Blood Transplant Study NCT00862719 | Indiana University School of Medicine | Phase 2 |
| Completed | Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation NCT00859586 | National Heart, Lung, and Blood Institute (NHLBI) | N/A |
| Terminated | SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED NCT00798213 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Oral Clofarabine for Acute Myeloid Leukemia NCT00727766 | Washington University School of Medicine | Phase 1 |
| Completed | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) NCT00864227 | Medical College of Wisconsin | Phase 2 |
| Completed | Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acut NCT00804856 | Boehringer Ingelheim | Phase 2 |
| Completed | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT NCT00849147 | Medical College of Wisconsin | Phase 2 |
| Completed | Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignan NCT00640796 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) NCT00691938 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment NCT00632749 | Boehringer Ingelheim | Phase 2 |
| Unknown | Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2 NCT00718250 | King's College Hospital NHS Trust | Phase 1 |
| Completed | Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Tr NCT00850304 | Tehran University of Medical Sciences | Phase 2 |
| Terminated | A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With My NCT00569179 | Indiana University School of Medicine | Phase 1 |
| Completed | AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia NCT00512252 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Terminated | Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysp NCT00915811 | King's College Hospital NHS Trust | Phase 2 |
| Completed | Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities NCT00546897 | Washington University School of Medicine | Phase 2 |
| Completed | BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukae NCT00701766 | Boehringer Ingelheim | Phase 2 |
| Completed | Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H NCT00458250 | Tehran University of Medical Sciences | Phase 1 |
| Completed | Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Ch NCT00915785 | King's College London | Phase 2 |
| Unknown | Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemi NCT00224614 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Terminated | Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) NCT00129948 | SGX Pharmaceuticals, Inc. | Phase 2 |
| Completed | Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) NCT00143975 | University of Ulm | Phase 2 |
| Completed | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malign NCT00241358 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation NCT01386619 | University Hospital, Basel, Switzerland | Phase 1 / Phase 2 |
| Recruiting | Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia NCT06956755 | Groupe Francophone des Myelodysplasies | — |